{"url_path":"/sec/clpt/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","accession_number":"0001193125-26-221890","cik":"0001285550","ticker":"CLPT","issuer_name":"ClearPoint Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","primary_entity_key":"0001285550","primary_entity_name":"ClearPoint Neuro, Inc."},"word_count":144,"has_tables":true,"body_markdown":"ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.\n\n(a) During the period covered by this report, following the completion of the working capital adjustment process, we issued 7,885 shares of our common stock to the former equityholders of IRRAS. For additional information regarding the IRRAS acquisition, see Note 3 “Business Combination” to the accompanying condensed consolidated financial statements. The former equity holders of IRRAS represented to us, among other things, that they are “accredited investors” as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act. The shares of common stock issued to the former equity holders of IRRAS were issued in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.\n\n(b) None.\n\n(c) None."}